Significant progression has been achieved in the treatment of metastatic colorectal cancer
(mCRC) in recent years. This has been partly attributed to successfully incorporating new …

Worldwide, colorectal cancer (CRC) is the third most commonly diagnosed cancer in male
individuals and the second most commonly diagnosed cancer in female individuals. Survival …

Worldwide, colorectal cancer (CRC) is the third most frequently diagnosed cancer in men
and the second in women. Metastatic disease develops in more than half of the patients and …

Introduction: Colorectal cancer (CRC) is currently the third most common cancer worldwide,
with up to 1 million new cases diagnosed each year. Despite improvements in clinical …

Background: Metastatic colorectal cancer (mCRC) represents a substantial health burden
globally and an increasing challenge in Asian countries. Treatment options include …

Bevacizumab is a monoclonal antibody that binds and neutralizes vascular endothelial
growth factor (VEGF)-A, a key player in the angiogenesis pathway. Despite benefits of …

Introduction Anti-angiogenic drugs are an efficacious class of therapy in the treatment of
patients with metastatic colorectal cancer (mCRC). Aflibercept, a vascular endothelial growth …

Studies carried out through the past two decades have evidenced that addition of
bevacizumab to chemotherapy improves the efficacy both in first-line and second-line …

Purpose: Aflibercept is a recombinant fusion protein of the VEGF receptor (VEGFR) 1 and
VEGFR2 extracellular domains. We assessed the safety and efficacy of aflibercept in …

Despite a decrease in incidence and mortality, colorectal cancer (CRC) still represents the
second leading cause of cancer worldwide. Recurrence following surgery and adjuvant …